Theravance Biopharma
TBPH
132 hedge funds and large institutions have $399M invested in Theravance Biopharma in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 46 reducing their positions, and 13 closing their positions.
211% more call options, than puts
Call options by funds: $118K | Put options by funds: $38K
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
9% more funds holding
Funds holding: 121 → 132 (+11)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 46
2.75% less ownership
Funds ownership: 99.61% → 96.86% (-2.7%)
7% less capital invested
Capital invested by funds: $431M → $399M (-$31.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$13.5M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$4.9M |
| 3 |
NM
Newtyn Management
New York
|
+$4.34M |
| 4 |
JP Morgan Chase
New York
|
+$2.06M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$21.6M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$10.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.17M |
| 4 |
BlackRock
New York
|
-$3.86M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$993K |
TBPH Hedge Fund Activity: Q2 2024 in Review
132 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2024, worth a combined $399M — down 7.2% from $431M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TBPH positions and 13 closed out — a net gain of 12 holders — while 43 added to existing stakes and 46 trimmed.
The largest buyer was Madison Avenue Partners, adding an estimated $13.5M. The largest seller was Baupost Group, cutting an estimated $21.6M.
- 132 institutional investors held Theravance Biopharma (TBPH) as of Q2 2024, up from 121 in Q1 2024.
- Funds reported $399M of Theravance Biopharma stock for Q2 2024, down 7.2% quarter-over-quarter.
- 25 funds opened new Theravance Biopharma positions in Q2 2024 and 13 closed out, a net change of +12 holders.
- The largest Theravance Biopharma buyer in Q2 2024 was Madison Avenue Partners, an estimated $13.5M added.
- The largest Theravance Biopharma seller in Q2 2024 was Baupost Group, an estimated $21.6M sold.
Based on aggregated 13F filings for Q2 2024.